<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908140</url>
  </required_header>
  <id_info>
    <org_study_id>M/40464/39</org_study_id>
    <secondary_id>2013-000116-14</secondary_id>
    <nct_id>NCT01908140</nct_id>
  </id_info>
  <brief_title>Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium
      bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic
      obstructive pulmonary disease (COPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Forced Expiratory Volume in One Second (FEV1) at Week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnoea Index (TDI) Focal Score at Week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 (&quot;major deterioration&quot;) to zero (&quot;no change&quot;) to +3 (&quot;major improvement&quot;). Category scores are added to compute the Focal Score (from -9 to 9)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">933</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Aclidinium Bromide / Formoterol Fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol / Fluticasone propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium Bromide / Formoterol Fumarate</intervention_name>
    <arm_group_label>Aclidinium Bromide / Formoterol Fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol / Fluticasone</intervention_name>
    <arm_group_label>Salmeterol / Fluticasone propionate</arm_group_label>
    <other_name>Seretide</other_name>
    <other_name>Advair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or non-pregnant, non-lactating female aged ≥40.

          -  Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years

          -  Patients with a clinical diagnosis of COPD according to GOLD guidelines 2013, with a
             post-bronchodilator FEV1 &lt;80%, and FEV1/FVC &lt; 70% at Screening Visits

          -  Symptomatic patients with a COPD assessment test (CAT) ≥10 at Screening and
             Randomisation Visits

          -  Patient must be able to perform repeatable pulmonary function testing for FEV1
             according to ATS/ERS 2005 criteria at Screening Visits

          -  Patients eligible and able to participate in the trial and who consent to do so in
             writing after the purpose and nature of the investigation have been explained

        Exclusion Criteria:

          -  History or current diagnosis of asthma

          -  Development of a respiratory tract infection or COPD exacerbation within 6 weeks (or 3
             months if hospitalisation was required) before the Screening Visit or during the
             run-in period

          -  Clinically significant respiratory conditions

          -  Type I or uncontrolled Type II diabetes, uncontrolled hypo- or hyperthyroidism,
             hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension

          -  Patients who, in the investigator's opinion, may need to start a pulmonary
             rehabilitation programme during the study and/or patients who started/finished it
             within 3 months prior to Screening Visit

          -  Use of long-term oxygen therapy (≥15 hours/day)

          -  Patients treated on daily basis with triple therapy (LABA+LAMA+ICS) within 4 weeks
             prior to the Screening Visit

          -  Patient who does not maintain regular day/night, waking/sleeping cycles including
             night shift workers

          -  Clinically significant cardiovascular conditions

          -  Patient with clinically relevant abnormalities in the results of the clinical
             laboratory tests, ECG parameters or in the physical examination at the Screening Visit

          -  Patient with a history of hypersensitivity reaction to inhaled anticholinergics,
             sympathomimetic amines, or inhaled medication or any component thereof (including
             report of paradoxical bronchospasm)

          -  Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute
             urinary retention, or patients with symptomatic non-stable prostatic hypertrophy

          -  Patient with known non-controlled history of infection with human immunodeficiency
             virus (HIV) and/or active hepatitis

          -  History of malignancy of any organ system (including lung cancer), treated or
             untreated, within the past 5 years other than basal or squamous cell skin cancer

          -  Patient with any other serious or uncontrolled physical or mental dysfunction

          -  Patient with a history (within 2 years prior to Screening Visit) of drug and/or
             alcohol abuse that may prevent study compliance based on investigator judgment

          -  Patient unlikely to be cooperative or that can't comply with the study procedures

          -  Patient treated with any investigational drug within 30 days (or 6 half-lives,
             whichever is longer) prior to Screening Visit

          -  Patient who intend to use any concomitant medication not permitted by this protocol or
             who have not undergone the required stabilization periods for prohibited medication

          -  Any other conditions that, in the investigator's opinion, might indicate the patient
             to be unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Global Medicines Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Feldbach</city>
        <zip>8330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Grieskirchen</city>
        <zip>A-4710</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Dimitrovgrad</city>
        <zip>6400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Kozlodui</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Petrich</city>
        <zip>2850</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Razgrad</city>
        <zip>7200</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Vidin</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>AB T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V7M 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>NB E1C 5K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M6H 3M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Saint Romuald</city>
        <state>Quebec</state>
        <zip>QC G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>QC G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Karlovy Vary</city>
        <zip>360 09</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Kralupy nad Vltavou</city>
        <zip>278 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Ostrava - Hrabuvka</city>
        <zip>700 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Rokycany</city>
        <zip>337 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Strakonice</city>
        <zip>386 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <zip>66025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Vieux Conde</city>
        <zip>59690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Cologne</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Cottbus</city>
        <zip>03050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>4357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Munich</city>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Schwabach</city>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1191</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Komárom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Pécs</city>
        <zip>H-7635</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Szazhalombatta</city>
        <zip>H-2400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Szigetszentmiklós</city>
        <zip>H-2310</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Vásárosnamény</city>
        <zip>4800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Trieste</city>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-01117</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-847</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Pila</city>
        <zip>64-920</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Proszowice</city>
        <zip>32-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-741</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Tczew</city>
        <zip>83-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Wilkowice-Bystra</city>
        <zip>43-365</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Belville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Gauteng</city>
        <zip>158</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Gauteng</city>
        <zip>1724</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Middelburg</city>
        <zip>1050</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03114</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Elda</city>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Laredo</city>
        <zip>39770</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <zip>08830</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>38008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Seville</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Middlesex</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site</name>
      <address>
        <city>Sidcup</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3947&amp;filename=LAC39_CSR_Synopsis.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <results_first_submitted>August 6, 2015</results_first_submitted>
  <results_first_submitted_qc>February 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2016</results_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 140 activated sites. A total of 121 sites randomised patients. The first patient was screened in Oct 2013 and the last patient visit was in Aug 2014.</recruitment_details>
      <pre_assignment_details>Patients fulfilling inclusion/exclusion criteria at the time of the screening visit were entered into a run-in period of 14-21 days to assess disease stability.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aclidinium Bromide / Formoterol Fumarate</title>
          <description>Experimental: Aclidinium Bromide / Formoterol Fumarate Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks</description>
        </group>
        <group group_id="P2">
          <title>Salmeterol / Fluticasone</title>
          <description>Active Comparator: Salmeterol / Fluticasone propionate Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="465"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="402"/>
                <participants group_id="P2" count="386"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other or Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with more than 1 treatment were analysed in the Safety population with the actual treatment assigned; for this reason, the Overall Number of Baseline Participants in the safety population is different than the randomised population.</population>
      <group_list>
        <group group_id="B1">
          <title>Aclidinium Bromide / Formoterol Fumarate</title>
          <description>Experimental: Aclidinium Bromide / Formoterol Fumarate Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks</description>
        </group>
        <group group_id="B2">
          <title>Salmeterol / Fluticasone</title>
          <description>Active Comparator: Salmeterol / Fluticasone propionate Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="467"/>
            <count group_id="B2" value="466"/>
            <count group_id="B3" value="933"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years), mean (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="8.1"/>
                    <measurement group_id="B2" value="63.3" spread="7.5"/>
                    <measurement group_id="B3" value="63.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Forced Expiratory Volume in One Second (FEV1) at Week 24</title>
        <description>Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration</description>
        <time_frame>At Week 24</time_frame>
        <population>ITT population: randomized patients who took at least one dose of IMP and have a baseline FEV1 assessment.
PP population: subset of ITT constituted by patients who met all inclusion/exclusion criteria liable to affect the efficacy ssessment, attained sufficient compliance to treatment and did not present serious deviations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide / Formoterol Fumarate</title>
            <description>Experimental: Aclidinium Bromide / Formoterol Fumarate Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol / Fluticasone</title>
            <description>Active Comparator: Salmeterol / Fluticasone propionate Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Expiratory Volume in One Second (FEV1) at Week 24</title>
          <description>Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration</description>
          <population>ITT population: randomized patients who took at least one dose of IMP and have a baseline FEV1 assessment.
PP population: subset of ITT constituted by patients who met all inclusion/exclusion criteria liable to affect the efficacy ssessment, attained sufficient compliance to treatment and did not present serious deviations of the protocol.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.655" spread="0.011"/>
                    <measurement group_id="O2" value="1.562" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This sample size of 900 had 90% power to show that the lower bound of the two-sided 95% confidence interval for the difference between Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg and SeretideTM AccuhalerTM (50/500 μg) in Peak FEV1 at 24 weeks is above -0,055 L</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority margin=-0,055 L</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <method_desc>If non-inferiority on the PP was achieved then switch to superiority was tested on the ITT.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnoea Index (TDI) Focal Score at Week 24</title>
        <description>The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 (“major deterioration”) to zero (“no change”) to +3 (“major improvement”). Category scores are added to compute the Focal Score (from -9 to 9)</description>
        <time_frame>At Week 24</time_frame>
        <population>PP population defined as a subset of ITT constituted by patients who met all inclusion/exclusion criteria liable to affect the efficacy ssessment, attained sufficient compliance to treatment and did not present serious deviations of the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide / Formoterol Fumarate</title>
            <description>Experimental: Aclidinium Bromide / Formoterol Fumarate Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol / Fluticasone</title>
            <description>Active Comparator: Salmeterol / Fluticasone propionate Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnoea Index (TDI) Focal Score at Week 24</title>
          <description>The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 (“major deterioration”) to zero (“no change”) to +3 (“major improvement”). Category scores are added to compute the Focal Score (from -9 to 9)</description>
          <population>PP population defined as a subset of ITT constituted by patients who met all inclusion/exclusion criteria liable to affect the efficacy ssessment, attained sufficient compliance to treatment and did not present serious deviations of the protocol.</population>
          <units>TDI Focal Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.17"/>
                    <measurement group_id="O2" value="1.9" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The total sample size provided 81% nominal power to show that the lower bound of the two-sided 95 confidence interval for the difference between Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and SeretideTM AccuhalerTM (50/500 μg) in transitional dyspnoea index (TDI) at 24 weeks is above -0,5</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority limit -0.5 units</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>MMRM</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks treatment + 2 weeks follow-up (±3 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aclidinium Bromide / Formoterol Fumarate</title>
          <description>Experimental: Aclidinium Bromide / Formoterol Fumarate Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks</description>
        </group>
        <group group_id="E2">
          <title>Salmeterol / Fluticasone</title>
          <description>Active Comparator: Salmeterol / Fluticasone propionate Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="467"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cor Pulmonale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Artrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Artrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmogenic right ventricular dysp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract and infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Grastroenteritis radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of head</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder depressive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD (exacerbation)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="467"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="467"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="466"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="467"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="467"/>
                <counts group_id="E2" subjects_affected="135" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="467"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="467"/>
                <counts group_id="E2" events="46" subjects_affected="32" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="82" subjects_affected="70" subjects_at_risk="467"/>
                <counts group_id="E2" events="81" subjects_affected="75" subjects_at_risk="466"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the information related to this clinical trial is considered strictly confidential and is the property of AstraZeneca. This information will not be given to a third party without the written consent of AstraZeneca. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and AstraZeneca.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

